Eli Lilly Targets Emerging Markets with Blockbuster Drug Expansion

Eli Lilly plans to launch its diabetes and weight-loss drug, Mounjaro, in emerging markets such as India, Brazil, and Mexico in 2025. The expansion leverages growing demand in populous countries facing rising obesity rates. Lilly aims to significantly boost sales with this strategic move.

Eli Lilly is set to make a significant impact on the global pharmaceutical market by introducing its blockbuster diabetes and weight-loss drug, Mounjaro, in key emerging economies by the latter half of 2025. This initiative is part of a larger strategy to meet the soaring global demand for effective obesity treatments.

The pharmaceutical giant sees a monumental opportunity in markets like India, Brazil, and Mexico, where obesity rates are escalating rapidly. CFO Lucas Montarce highlighted the potential to reach around 900 million patients with its upcoming launch. The move aligns with Lilly's broader goal to penetrate big emerging markets and fuel company growth through to 2026.

Following limited launches in China and other markets, Eli Lilly is doubling down on efforts to expand production capabilities worldwide, having invested over $23 billion since 2020. The company predicts annual sales to reach between $58 billion and $61 billion by 2025, with plants in Ireland, Italy, and Spain supporting its global expansion.

(With inputs from agencies.)